on OXURION (EBR:OXUR)
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Leuven, Belgium - April 2, 2025 - Oxurion NV, a biopharmaceutical company listed on the Brussels Stock Exchange, announced the receipt of a transparency notification from Atlas Special Opportunities II LLC. According to this notification, as of March 31, 2025, Atlas held 925,088 shares out of a total of 4,634,633 shares outstanding, thus falling below the 20% threshold after the sale of voting securities.
Oxurion, based in Leuven, specializes in the development of ophthalmic therapies to treat retinal diseases. This press release provides information on compliance with Belgian transparency regulations in stock market transactions.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news